Company Overview: SPERO THERAP.INC.

Seite 1 von 1
neuester Beitrag: 05.11.19 21:38
eröffnet am: 15.10.18 21:49 von: Absaufklaus. Anzahl Beiträge: 4
neuester Beitrag: 05.11.19 21:38 von: Balu4u Leser gesamt: 1304
davon Heute: 1
bewertet mit 1 Stern

15.10.18 21:49

5646 Postings, 2358 Tage AbsaufklauselCompany Overview: SPERO THERAP.INC.

Company Overview: US84833T1034
Spero Therapeutics, Inc. (SPRO) is a Cambridge, Massachusetts based early clinical-stage biopharmaceutical company focused on developing treatments for multidrug resistant (NYSE:MDR) bacterial infections. The company was formed in 2013 and currently carries a market cap of ~$200 million. Spero came public in November 2017, netting $74.4 million at $14 per share. In early July, Spero raised ~$75 million in a secondary offering of preferred shares and common stock. The common was priced at $12.50 a share.

-Antibiotics concern Spero Therapeutics recently used a positive interim Phase 1 readout on its lead candidate (SPR994) as an opportunity to execute a secondary offering.
- The shares dropped some 35% as a result of this capital raise.
- However, the company has a slightly de-risked, primary drug candidate likely headed for approval, is cash rich and has strategic partnerships.

We take a deeper look at this 'Tier 4' developmental concern focused on multidrug bacterial infections in the paragraphs before.  

16.07.19 13:25

1262 Postings, 1899 Tage moggemeisNovo Nordisk Repair Impact Fonds

Spero findet sich im Portfolio des NN Reair-Impact- Fonds.  

   Antwort einfügen - nach oben